ACST Stock – (NASDAQ: ACST) is giving an update on the use
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually giving an update on the use of the “at the market” equity of its providing plan.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice a “at the market” equity offering system under which Acasti may well issue and promote from time to time the common shares of its having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions reported on January twenty seven, 2021, Acasti granted an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares were marketed at prevailing market costs averaging US$1.0747 per share. No securities were marketed through the facilities of the TSXV or, to the understanding of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a result of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and great as of March 5, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and will deliver the Company with extra freedom in its ongoing review process to enjoy and evaluate strategic alternatives.
About Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescribed drugs using OM3 greasy acids delivered both as free fatty acids and bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have substantial clinical proof of efficacy and safety for lowering triglycerides in people with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being created for clients with serious HTG.
Forward Looking Statements – ACST Stock
Statements in that press release which are not statements of historical or current truth constitute “forward-looking information” within the meaning of Canadian securities laws and “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking statements include known and unknown risks, uncertainties, as well as other unknown factors that might result in the actual results of Acasti to be materially different from historical success or from any later results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks as well as uncertainties, people are actually urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other related expressions to be uncertain and forward-looking. People are actually cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the date of this particular press release. Forward-looking claims in that press release include, but aren’t limited to, statements or info about Acasti’s strategy, future operations as well as its review of strategic options.
The forward looking assertions found in this press release are expressly qualified in the entirety of theirs by this alerting statement, the “Special Note Regarding Forward-Looking Statements” area in Acasti’s newest annual report on Form 10 K and quarterly report on Form 10 Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor section of Acasti’s website at www.acastipharma.com. Many forward-looking statements in that press release are produced as of the particular date of this press release.
ACST Stock – Acasti does not undertake to upgrade any such forward-looking statements whether as a result of info that is brand new , future events or even otherwise, except as called for by law. The forward-looking assertions contained herein are also subject generally to risks and assumptions as well as uncertainties that are described from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, like Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the use